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httpcense.Abstract Background and objective: Malignant pleural effusion (MPE) is a common problem in
patients with malignancies. Chemical pleurodesis is the most commonly used palliative option. Par-
enteral tetracycline (TET) and doxycycline (DOX) are cost-effective and safe in producing pleurod-
esis but mostly unavailable currently. We investigated whether oral doxycycline could produce an
efﬁcient and safe pleurodesis as does parenteral doxycycline, which is currently unavailable in many
countries.
Methods: A prospective study of 24 pleurodesis procedures in 22 patients with malignant pleural
effusions were conducted over a 3-year period. All pleurodesis was performed with oral forms of
doxycycline as the sclerosing agent, where about 1000 mg of doxycycline was taken and prepared
from the oral preparation (vibramycin 100 mg/capsule) and mixed in 50 ml. Physiological saline
was then administered via tube thoracostomy. We assessed the success or failure of pleurodesis
in addition to the frequency of complications and survival. Post-pleurodesis postero-anterior
(PA) radiographs were obtained after tube removal and 30 days following the procedure.
Results: Twenty-two patients were included (6 women, 16 men), the mean age was (62.5 years).
Origins of MPE were: lung and pleura 8 (36.4%), breast 2 (9.1%), ovarian 2 (9.1%), digestive 3
(13.6%), lymphoma 3 (13.6%) and unknown 4 (18.2%). No immediate perioperative complications
were noted. Chest tube duration averaged 4.2 ± 2.6 days. Immediate postoperative events included
chest pain in 10patients (45.5%), fever in 2 (9.1%)patients, pain and fever in 5patients (22.7%). Sixteen
patients (72.7%) had successful pleurodesis and 6 patients (27.3%) had failed pleurodesis at 1 month.
Conclusions: Pleurodesis with oral forms of doxycycline dissolved in sterile saline solution have a
high success rate with a low incidence of complications and could be a good option as palliative therapy
in patients with symptomatic malignant pleural effusions.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Open access under CC BY-NC-ND license.01223836717.
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Malignant pleural effusions (MPEs) affect approximately
150,000 patients each year in the United States [1]. Lung and
breast cancer account for 50–65% of all MPEs, with lympho-
mas, cancers of the genitourinary andGI tract, and cancers with
unknown primaries accounting for the majority of the remain-
ing causes of MPE [2]. Although up to 25% of patients are ini-
tially asymptomatic from the effusion, nearly 100% of patients
will experience debilitating dyspnea [3]. Despite management of
the underlyingmalignancy with chemotherapy and/or radiation
therapy, MPEs tend to persist or recur and require local pallia-
tive procedures to control symptoms. Currently available tech-
niques for palliating the dyspnea that is associated with MPE
include (1) repeated thoracentesis, (2) pleurodesis, and (3) inser-
tion of tunneled pleural catheters (TPCs) [4].
Pleurodesis is the obliteration of the pleural space by fusion
of the visceral and parietal pleurae with ﬁbrous tissue. Recur-
rent and symptomatic effusions and pneumothoraces are indi-
cations for pleurodesis. Most of the agents used for
pleurodesis injure the pleura and cause an inﬂammatory reac-
tion together with a pleural effusion. Subsequently, the local
activation of the coagulation system and the production of ﬁbr-
ogenic cytokines such as trans-forming growth factor b lead to
the production of collagen that can result in a pleurodesis [5].
Currently talc [6], tetracycline derivatives [7], and bleomy-
cin [8] are the most frequently used sclerosing agents. Bleomy-
cin is more expensive and less efﬁcient than tetracycline
derivatives or talc [5]. The intrapleural injection of talc can
cause ARDS and death [9,10]. Tetracycline (35 mg/kg) was
the most effective compound when original animal experi-
ments on producing pleurodesis in rabbits were performed
[11,12]. The parenteral form of tetracycline is currently not
available in most countries. Subsequently, parenteral doxycy-
cline was used for pleurodesis at an approximate dose of
10 mg/kg and was shown to have comparable effectiveness
with tetracycline at 35 mg/kg. [7,8]. However, parenteral doxy-
cycline is also not available currently in many parts of the
world. In contrast, doxycycline capsules are available world-
wide but (to our knowledge) have never been tested for their
efﬁcacy and safety in producing pleurodesis in humans when
administered via tube thoracostomy. We investigated whether
oral doxycycline could produce an efﬁcient and safe pleurode-
sis as does parenteral doxycycline, which is currently unavail-
able in many countries.Subjects and methods
Study population
A prospective study of 24 pleurodesis procedures in 22 patients
with malignant pleural effusions were conducted over a 3-year
period from May 2009 to June 2012 at the Dallah Hospital,
Riyadh, Saudi Arabia. The cause of the malignant pleural effu-
sions was conﬁrmed in all patients with cancer, either by cyto-
logic examination of pleural ﬂuid or by needle pleural biopsy
or during a previous recent thoracic evaluation. Criteria for
consideration as a candidate for pleurodesis in patients with
malignant pleural effusions were as follows: (1) anticipated
survival longer than 1 month after performance of the pleurod-esis; (2) improved respiratory symptoms after a previous ther-
apeutic thoracentesis; (3) cytologic or histologic conﬁrmation
of the malignant nature of the pleural effusion; and (4) ability
to fully re-expand the lung during drainage of pleural ﬂuid by
tube thoracostomy [7].
Procedures and assessments
A size 24F to 28F thoracostomy tube was placed through the
seventh or eighth intercostal space at the posterior axillary line
and was attached to a water seal with gravity drainage. Pleural
ﬂuid volumes were recorded daily, and a chest radiography was
taken daily. When the drainage fell below 100 ml/24 h and the
lung had expanded completely, pleurodesis was attempted.
After instillation of 10 ml of 1% lidocaine, about 1000 mg of
doxycycline were taken and prepared from the oral preparation
(10 capsules of vibramycin 100 mg/capsule) and mixed in 50 ml
physiological saline under sterile conditions then administered
via a large syringe, followed by a 30–50 ml of a sterile saline
ﬂush. The tube was clamped for 2 h, then unclamped and grav-
ity drainage resumed. The chest tube was removed when the
drainage fell below 100 ml/24 h and chest X-ray showed com-
plete lung expansion. Patients were observed for complications,
were medicated for pain as needed, and were monitored with
daily chest radiographs. In two patients, in whom drainage of
the pleural ﬂuid did not diminish below 100 ml/day during
the 24–72 h after the initial attempt at pleurodesis, a second
intrapleural instillation of doxycycline (500 mg) was used.
Post-pleurodesis postero-anterior (PA) radiographs were ob-
tained after tube removal and 30 days following the procedure.
Radiographic response at day 30 was classiﬁed as successful: no
or only minor re-accumulation of pleural ﬂuid, or non-success-
ful: re-accumulation of ﬂuid. Minor re-accumulation refers to
re-accumulation of ﬂuid, without symptoms or not requiring
repeat drainage, above the post-sclerotherapy level but below
the original level [13].
Statistical analysis
The data were expressed as mean ± SD. All data were ana-
lyzed with statistical software (Sigma Stat; SPSS; Chicago,
IL). A p value < 0.05 was considered signiﬁcant.Results
A total of 22 patients were included in this study, of which 16
(72.7%) were males and 6 (27.3%) were females. The mean age
for the entire group was 62.5 ± 6.5 years. Pleural effusions
were right sided in 10 (45.5%) cases while 12 (54.5%) cases
were left sided. Origins of MPE were: lung and pleura 8
(36.4%), breast 2 (9.1%), ovarian 2 (9.1%), digestive 3
(13.6%), lymphoma 3 (13.6%) and undifferentiated carcinoma
of unknown primary 4 (18.2%). (Table 1):
Sixteen patients (72.7%) had successful pleurodesis and 6
patients (27.3%) had failed pleurodesis at 1 month (Table 2).
No immediate perioperative complications were noted.
Chest tube duration averaged 4.2 ± 2.6 days. Immediate post-
operative events included chest pain in 10 patients (45.5%),
fever in 2 (9.1%) patients, pain and fever in 5 patients
(22.7%) (Table 3).
Table 1 Clinical demographics of the study patients (n= 22).
Number of patients 22
Sex, n (%)
Male 16 (72.7%)
Female 6 (27.3%)
Age, years 62.5 ± 6.5
Primary tumor, n (%)
Malignant mesothelioma 2 (9.1%)
Bronchogenic carcinoma 6 (27.3%)
Breast 2 (9.1%)
Ovarian 2 (9.1%)
Digestive 3 (13.6%)
Lymphoma 3 (13.6%)
Unknown 4 (18.2%)
Response, n (%)
Successful pleurodesis 16 (72.7%)
Failed pleurodesis 6 (27.3%)
Table 2 Results of doxycycline pleurodesis at 1 month.
Diagnosis Failed pleurodesis Successful pleurodesis
Lung cancer 6 (27.3%) 2 4 (18.2%)
m. mesothelioma 2 (9.1%) 0 2 (9.1%)
breast cancer 2 (9.1%) 1 1 (4.5%)
Ovarian 2 (9.1%) 0 2 (9.1%)
Digestive 3 (13.6%) 1 2(9.1%)
Lymphoma 3 (13.6%) 1 2 (9.1%)
Unknown 4 (18.2%) 1 3 (13.6%)
Total 22 (100%) 6 (27.3%) 16 (72.7)
Table 3 Adverse effects of doxycycline pleurodesis.
Diagnosis Adverse eﬀects
Non Pain Fever Pain and fever
Lung cancer 2 3 0 1
M. mesothelioma 0 1 1
Breast cancer 0 2 0 0
Ovarian 0 1 0 1
Digestive 1 1 0 1
Lymphoma 1 1 0 1
Unknown 1 1 2 0
Total 22 (100%) 5 (22.7%) 10 (45.5%) 2 (9.1%) 5 22.7%
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Our study demonstrates that oral forms of doxycycline are as
effective and safe as parenteral doxycycline in producing pleu-
rodesis. The oral forms are less expensive and more widely
available than the parenteral forms. It is likely that these
results can be widely applied for malignant pleural effusion
management, since parenteral tetracycline [14,15] and doxycy-
cline [7,8] have been extensively studied and shown to be effec-
tive and safe in producing pleurodesis in patients with
malignant pleural effusion.
If pleurodesis is attempted, what agent should be used? Talc
is the sclerosing agent most commonly used for chemical pleu-
rodesis by pulmonologists [16,17]. The reason that talc is the
most popular agent is that it is widely available, inexpensive,and perceived to be effective. One concern about talc is that its
intrapleural administration has been associated with the devel-
opment of ARDS and death in some patients. The incidence
of ARDS has varied markedly from series to series, and most
of the reported cases have been from the United States [9,10].
Many different agents have been injected intrapleurally in
attempts to create a pleurodesis, including the tetracycline
derivatives [6–8], silver nitrate [18], iodopovidone [19] and ble-
omycin [8]. There is no convincing evidence that talc is supe-
rior to other agents, because there have been very few
randomized controlled studies comparing the different agents.
Whatever sclerosing agent is used, complete drainage of the
pleural effusion is considered crucial for successful pleurodesis.
Many investigators showed that intrapleural instillation of
doxycycline is safe and effective for pleurodesis in malignant
effusions. In this work, a new method for doxycycline delivery
to the pleura was used where about 1000 mg of doxycycline
was taken and prepared from the oral preparation (10 capsules
of vibramycin 100 mg/capsule) and mixed in 50 ml physiolog-
ical saline under sterile conditions then administered via tube
thoracostomy.
In this study, the oral forms of doxycycline pleurodesis were
successful in sixteen patients (72.7%) at 1 month. The effective-
ness of intrapleural doxycycline observed in this study in pa-
tients with malignant pleural effusions is similar to previous
reports that used parenteral doxycycline as a sclerosing agent.
Heffner et al. [7] examined the outcome in 31 patients receiving
doxycycline through a chest tube for malignant pleural effu-
sions or persistent bronchopleural ﬁstulae. Of the 27 patients
with malignant pleural effusions, 21 patients had successful
pleurodesis (77.8%) at 1 month. Costa et al. [20] treated 41
malignant pleural effusion patients with doxycycline pleurode-
sis. A successful pleurodesis (complete or partial) was accom-
plished in 25 (61%). Porcel et al. [21] conducted a prospective
study of 36 rapid pleurodesis procedures in 34 patients with
malignant pleural effusions. Patients received 500 mg of intra-
pleural doxycycline. Complete success of pleurodesis was
achieved in (55%), partial success in (26%), and failure in
(19%). Thus, the overall success rate of pleurodesis was 81%.
Recently, Elnady and Sakr [22], performed pleurodesis in
twenty-seven patients with malignant pleural effusion.
Thoracoscopy was performed for diagnosis and subsequent
doxycycline pleurodesis. At the end of thoracoscopy, a new
method for doxycycline delivery to the pleura was used through
a pneumatic atomizer insufﬂations at the end of thoracoscopy
(thoracoscopic doxycycline poudrage ‘‘TDP’’) where about
500–1000 mg of doxycycline was taken and prepared as a pow-
der from the oral preparation (vibramycin 100 mg/capsule).
74.1% had a successful pleurodesis, 18.5% had partial response
and 7.4% had failed pleurodesis at 1 month.
Since thoracoscopy is not widely available and needs
trained pulmonologists, so doxycycline pleurodesis via tube
thoracostomy is much more easier, less expensive with shorter
hospital stay.
To our knowledge, Doxycycline prepared from the oral
preparation and administered via tube thoracostomy had
never been tested for their efﬁcacy and safety in producing
pleurodesis in humans. Moreover, the success rate obtained
in our study matched that of the literature for parenteral
doxycycline.
How doxycycline initiates pleural symphysis is uncertain.
Analogous to tetracycline, doxycycline may damage
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cesses through cytostatic effects that have been demonstrated
for tetracycline [23], as suggested by observations that intra-
pleural heparin or urokinase interferes with Tetracycline in-
duced pleurodesis in animals. Doxycycline may interact with
intrapleural thrombotic or ﬁbrinolytic processes and induce
pleurodesis [24]. Tetracycline has been shown to stimulate mes-
othelial cell release of growth factors for ﬁbroblast proliferation
and deposition of collagen [25]. Furthermore, doxycycline has a
capacity to inhibit matrix-degrading metalloproteinases and to
promote unopposed collagen and ﬁbrin deposition in the in-
ﬂamed pleural space [26]. Tetracycline and doxycycline are
dose-dependent effective inhibitors of matrix-degrading
metalloproteinase (MMP) activity in the pleural ﬂuid. Thus,
the pleural ﬁbrotic process needed for pleurodesis is augmented
by the reduction of MMP activity that favors remodeling
through normal repair of the tissue rather than ﬁbrosis [27].
Pain observed in 10 cases (45.5%) was due to chest tubing
or the tumor itself rather than doxycycline powder. Analgesics,
prescribed in general for 24 h, easily overcame this problem. A
fever greater than 38.5 C lasting for about 24 h was a re-
corded complication in 2 cases (9.1%) but it was easily con-
trolled with paracetamol. Pain and fever were noticed in 5
cases (22.7%) as shown in Table 3.
In conclusion, the present study demonstrates that the intra-
pleural injection of the oral forms of doxycycline dissolved in
sterile saline solution produces a pleurodesis that is comparable
to that produced by the intrapleural injection of parenteral
doxycycline with a high success rate and low incidence of com-
plications and could be a good option as palliative therapy in
patients with symptomatic malignant pleural effusions pro-
vided that meticulous care for avoiding infection is exercised.
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